IONIS PHARMACEUTICALS INC (IONS)
US4622221004 - Common Stock
We assign a fundamental rating of 3 out of 10 to IONS. IONS was compared to 565 industry peers in the Biotechnology industry. While IONS seems to be doing ok healthwise, there are quite some concerns on its profitability. IONS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IONS has reported negative net income.
In the past year IONS has reported a negative cash flow from operations.
In the past 5 years IONS reported 4 times negative net income.
In multiple years IONS reported negative operating cash flow during the last 5 years.
1.2 Ratios
IONS's Return On Assets of -11.65% is amongst the best of the industry. IONS outperforms 86.99% of its industry peers.
IONS has a Return On Equity of -54.16%. This is in the better half of the industry: IONS outperforms 65.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.65% | ||
| ROE | -54.16% | ||
| ROIC | N/A |
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IONS has a better Gross Margin (98.70%) than 98.04% of its industry peers.
IONS's Gross Margin has been stable in the last couple of years.
IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IONS has more shares outstanding
Compared to 5 years ago, IONS has more shares outstanding
IONS has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.16, we must say that IONS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IONS (1.16) is better than 68.27% of its industry peers.
A Debt/Equity ratio of 1.86 is on the high side and indicates that IONS has dependencies on debt financing.
IONS's Debt to Equity ratio of 1.86 is on the low side compared to the rest of the industry. IONS is outperformed by 81.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.86 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.16 |
ROIC/WACCN/A
WACC9.45%
2.3 Liquidity
IONS has a Current Ratio of 8.91. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.91, IONS is doing good in the industry, outperforming 77.01% of the companies in the same industry.
A Quick Ratio of 8.82 indicates that IONS has no problem at all paying its short term obligations.
IONS's Quick ratio of 8.82 is fine compared to the rest of the industry. IONS outperforms 77.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.91 | ||
| Quick Ratio | 8.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.79% over the past year.
IONS shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.58%.
IONS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.77%
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Sales Q2Q%-6.94%
3.2 Future
Based on estimates for the next years, IONS will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.89% on average per year.
IONS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-40.16%
EPS Next 2Y-22.11%
EPS Next 3Y-2.39%
EPS Next 5Y19.89%
Revenue Next Year-1.66%
Revenue Next 2Y6.95%
Revenue Next 3Y13.97%
Revenue Next 5Y22.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IONS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IONS's earnings are expected to decrease with -2.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.11%
EPS Next 3Y-2.39%
5. Dividend
5.1 Amount
No dividends for IONS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IONIS PHARMACEUTICALS INC
NASDAQ:IONS (11/22/2024, 4:48:38 PM)
After market: 34.01 0 (0%)34.01
+0.07 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.65% | ||
| ROE | -54.16% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.7% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.86 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.91 | ||
| Quick Ratio | 8.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-40.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y